We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept

Nagpur, March 25, 2019: ZIM Laboratories, a specialty pharma R&D company focused on a novel drug delivery system, today announced that it has signed an exclusive agreement in Europe with Neuraxpharm, a European specialty pharmaceutical company focusing on central nervous system (CNS) disorders. The agreement is for the co-development and commercialization of novel oral thin films (OTF) based products with ZIM Laboratories’ patented technology.

As per the agreement, ZIM Laboratories will develop a novel delivery system in the form of OTF for a molecule, to be used as opioid substitution treatment in illicit drug dependant patients. This unique delivery system, developed by ZIM Laboratories’ patented OTF technology, will address medical needs of physicians and patients which are currently not being served. The new delivery system will enhance patient convenience and, at the same time, will be preferred by the regulators for its unique features.

Commenting on the development, Dr. Anwar Daud, Chairman & Managing Director, ZIM Laboratories said, “I am very happy that our patented OTF technology is getting global recognition and acceptance. The co-development agreement with Neuraxpharm is a step towards ZIM Laboratories’ global aspirations of becoming a preferred partner globally for new drug delivery systems.”

Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: “We are very pleased to partner with ZIM Laboratories to develop this novel drug delivery system. Oral thin films have the potential to improve the compliance and the safety of the medication of patients by better avoiding a misuse of the drug”.

The growing market size for the molecule in Europe is more than 120 million Euro.

Please find below the press release in English